Browsing by Author "Vera, Alejandra"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Dynamics and Orientation of Parathion Dissolved in a Discotic Nematic Lyomesophase
    (2008) Vera, Alejandra; Ahumada, Hernan; Bahamonde, Victor; Montecinos Escobar, Rodrigo Andrés; Araya Maturana, Ramiro; Munoz, Daniel; Weiss-Lopez, Boris E.
  • Thumbnail Image
    Item
    HLA-B*5701 frequency in Chilean HIV-infected patients and in general population
    (CONTEXTO, 2010) Poggi, Helena; Vera, Alejandra; Lagos, Marcela; Solari, Sandra; Rodriguez P, Luis; Perez, Carlos M.
    It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients. The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naive HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR. We detected 14/300 (4.7%) B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) had another subtype. All were heterozygous, thus a B*5701 allele frequency of 2% was determined. Eleven of 492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population, and the availability of a validated method, we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.